Trial Profile
A Pilot Study to Evaluate the Potential of Montelukast to Prevent the Development of Nasal Symptomatology During Natural Viral Upper Respiratory Infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Montelukast (Primary)
- Indications Respiratory tract infections
- Focus Therapeutic Use
- 22 Oct 2014 New trial record